Tüdőrák: vizsgálatok itt: Franciaország
318 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Dijon, Paris, Rennes, Villejuif
- Életkor
- 18 év and over
- People
- 623 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of IAM1363 in HER2 Cancers
- Where
- Dijon, Saint-Herblain, Toulouse
- Életkor
- 18 év and over
- People
- 463 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 · EU 2024-519188-17-00 - 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Angers, Avignon Cedex 9, La Roche Sur Yon Cedex 9, Marseille, Vantoux
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Caen, Lille, Lyon, Paris Cedex 13, Saint-Herblain Cedex, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - No phaseTaking peopleUmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
- Where
- Aix-en-Provence, Angers, Aurillac, Auxerre, Avignon, Bezannes, Béziers, Blois, Bordeaux, Boulogne-Billancourt, Bourg-en-Bresse, Caen, Carcassonne, Chalon Sur Sa Ne, Chambéry, Châteauroux, Créteil, Dieppe, Dinan, Dreux, Epagny METZ Tessy, FORT de France, Le Coudray, Limoges, Lyon, Marseille, Meaux, Metz, Mulhouse, Nancy, Nantes, Neuilly-sur-Seine, Nice, N MES, Paris, Perpignan, Reims, Rouen, Saint-Brieuc, Saint-Etienne, Saint-Herblain, Strasbourg, Suresnes, Toulouse, Troyes, Valenciennes, Vandœuvre-lès-Nancy, Vannes, Villefranche-sur-Saône, Villeurbanne
- Életkor
- 18 év and over
- People
- 300
- Run by
- AstraZeneca
See details and how to joinNCT06726720 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Amiens Cedex 1, Angers, Boulogne-Billancourt, Brest, Caen Cedex 5, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Mulhouse, Paris, Saint-Herblain, Vandoeuvre Les Nancy, Villejuif
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisNot yet taking people in FranciaországA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Bordeaux, Dijon, Lyon, Paris, Suresnes
- Életkor
- 18 év and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - 2. fázisNot yet taking people in FranciaországA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
- Where
- Marseille, Nice, Paris, Pessac, Villefranche-sur-Saône
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07941609 - 1. fázisNot yet taking people in FranciaországLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Pessac
- People
- 12 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 - 3. fázisNot yet taking people in FranciaországA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- Amiens, Caen Cedex 5, Créteil, Limoges, Montpellier Cedex 5, Paris, Rennes Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - 3. fázisTaking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Créteil, Limoges, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Strasbourg
- Életkor
- 18 év and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - 3. fázisTaking peopleA Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- Where
- Angers, Bordeaux, Le Mans Cedex 9, Lyon, Vantoux
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00 - 2/3. fázisNot yet taking people in FranciaországA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Montpellier Cedex 5, Mougins, Paris, Villefranche Sur Saone Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - 3. fázisTaking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Amiens, Boulogne-Billancourt, Caen Cedex 5, Créteil, Marseille, Montpellier, Orleans Cedex 2, Pessac, Saint-Herblain, Toulon Cedex 9, Vandoeuvre Les Nancy Cedex
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - 3. fázisTaking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Clermont-Ferrand, Dijon, Paris, Pessac, Rennes, Suresnes, Toulouse, Vandoeuvre Les Nancy
- Életkor
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - 2. fázisNot yet taking people in FranciaországA trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
- Where
- Marseille, Nice, Paris, Pessac, Villefranche Sur Saone Cedex
- Életkor
- 18 év and over
- People
- 146 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524836-21-00 - 3. fázisTaking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Bayonne, Besancon Cedex, Boulogne-Billancourt, Brest, Caen Cedex 9, Chambéry, Créteil, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Nîmes, Orleans Cedex 2, Paris, Paris Cedex 14, Paris Cedex 20, Pessac, Poitiers, Quimper Cedex, Reims Cedex, Rennes, Rouen Cedex, Saint-Grégoire, Saint-Priest-en-Jarez, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Toulouse Cedex 3, Tours Cedex 9, Villefranche sur Saône, Villejuif
- Életkor
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - 2/3. fázisTaking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Besancon Cedex, Brest Cedex 2, Caen Cedex 5, Clermont-Ferrand, Créteil, Dijon, Marseille, Montpellier Cedex 5, Nice, Paris, Pessac, Pierre-Bénite, Reims, Rennes, Toulouse, Tours, Vandoeuvre Les Nancy Cedex, Villejuif Cedex
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - 2. fázisNot yet taking people in FranciaországA Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
- Where
- Bordeaux, Lyon, Nice Cedex 2, Paris, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 200
- Run by
- Centre Leon Berard
See details and how to joinNCT07936422 · EU 2025-522058-38-00 - 1. fázisFut, nem toborozBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Bron, Lyon, Marseille, Paris, Rennes, Villejuif Cedex
- Életkor
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - 1/2. fázisFut, nem toborozFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Bordeaux, Lyon, Paris, Saint-Herblain, Villejuif
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - 3. fázisTaking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Avignon, Boulogne-Billancourt, Clermont Ferrand Cedex1, Dijon, Nice, Nimes Cedex 9, Quimper Cedex, Valenciennes
- Életkor
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - 3. fázisTaking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Avignon, Bayonne, Besançon, Bobigny, Brest, Bron, Cholet, Créteil, La Roche-sur-Yon, La Tronche, Le Mans, Limoges, Lyon, Marseille, Montpellier, Mulhouse, Nancy, Nantes, Paris, Pessac, Poitiers, Rennes, Saint-Herblain, Strasbourg, Toulon, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - 3. fázisTaking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Cholet, Creteil Cedex, Marseille, Montpellier, Nice Cedex 2, Paris, Pessac, Quimper Cedex, Rennes, Saint-Herblain, Saint-Herblain Cedex, Toulon, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00